All In Biotech

Drug Trial Radar · NCT07257939

NTI164 in Autism Spectrum Disorder

A Phase III Double-blind, Randomised, Placebo-controlled Study Investigating the Efficacy and Safety of NTI164 in Children and Young Adults With Autism Spectrum Disorder

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Jul 1, 2029

Study completion Jul 1, 2030

Sponsor

Lead sponsor
Fenix Innovation GroupIndustry
Sponsor type
Industry
Collaborators
Neurotech International Limited
First posted
Dec 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, randomised, placebo-controlled study investigating the efficacy of a full-spectrum medicinal cannabis plant extract on core and associated ASD symptoms over placebo. Participants will be randomly allocated to either NTI164 or placebo at a 1:1 ratio and blood samples will be collected and surveys completed at baseline and Week 16. This study will expand efficacy and safety data of NTI164 and provide additional mechanism of action data of NTI164 in this patient cohort.

Conditions

  • Autism
  • Autism Spectrum Disorder
  • Autism Disorder

Interventions

  • NTI164Drug

    A CBDA-dominant full-spectrum medicinal cannabis plant extract with extremely low THC.

  • PlaceboDrug

    Placebo oil suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Vineland Adaptive Behaviour Scales, 3rd Edition (Vineland-3)Time frame: Baseline, Week 16

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Queensland

    Brisbane, Queensland, Australia

  • Sunshine Coast University Hospital

    Sunshine Coast, Queensland, Australia

  • Monash Health

    Clayton, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.